<DOC>
	<DOCNO>NCT03052530</DOCNO>
	<brief_summary>A prospective , open label , multi-center , single arm , observational study design evaluate acute safety device procedural success Sapphire II PRO 1.0 1.25 mm PTCA dilatation catheter subject stenotic coronary artery bypass graft percutaneous coronary intervention . Sixty ( 60 ) subject treat 5 U.S. site Sapphire II PRO diameters 1.0 1.25 mm PTCA dilatation catheter pre-dilate coronary artery bypass graft index procedure . All subject screen accord protocol inclusion exclusion criterion follow hospital discharge .</brief_summary>
	<brief_title>Sapphire II PRO US Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>Clinical 1 . Subject ≥ 18 year age . 2 . Subject legally authorize representative must provide write informed consent prior study related procedure . 3 . Subject must agree participate clinical study hospitalization index procedure would interfere endpoint study . 4 . Subjects must single double vessel coronary artery disease clinical evidence ischemic heart disease , stable / unstable angina silent ischemia . Angiographic Inclusion Criteria 5 . Subject must de novo restenotic lesion ( ) native coronary artery bypass graft suitable percutaneous coronary intervention . An embolic protection device must use Saphenous venous graft ( SVG ) intervention perform index procedure . 6 . A maximum two lesion , include least one target lesion , two coronary artery . 7 . Target nontarget lesion must locate different coronary artery bypass graft . 8 . Target lesion ( ) must diameter stenosis ≥70 % visual estimation may include chronic total occlusion ( CTO ) 9 . Treatment nontarget lesion , , must complete prior treatment target lesion must deem clinical angiographic success . Clinical 1 . Subject know hypersensitivity contraindication aspirin , heparin , bivalirudin , antiplatelet medication , sensitivity contrast medium adequately premedicated . 2 . Subject know diagnosis acute myocardial infarction ( AMI ) within 72 hour prior index procedure . 3 . Subject known pregnancy nursing . Women child bear potential document negative pregnancy test within 7 day index procedure . 4 . Planned actual target lesion treatment unapproved device , atherectomy , laser , cut balloon thrombectomy index procedure . 5 . A serum creatinine level &gt; 2.0 mg/dl within seven day prior index procedure . 6 . Cerebrovascular accident ( CVA ) within past 6 month . 7 . Active peptic ulcer active gastrointestinal ( GI ) bleed within past 6 month . 8 . Subject know leave ventricular ejection fraction ( LVEF ) &lt; 30 % ( LVEF may obtain time index procedure value unknown , necessary ) Angiographic Exclusion Criteria 9 . More two lesion require treatment . 10 . Unprotected leave main coronary artery disease . ( Greater 50 % diameter stenosis ) 11 . Coronary artery spasm target vessel absence significant stenosis . 12 . Target lesion angiographic presence probable definite thrombus . 13 . Target lesion involve bifurcation require treatment one stent predilatation side branch &gt; 2.0 mm diameter . 14 . Nontarget lesion treat index procedure meet follow criterion : Located within bypass graft ( venous arterial ) Left main location Chronic total occlusion Involves bifurcation ( e.g. , bifurcation require treatment 1 stent ) Treatment deem clinical angiographic success</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>